Menarini Group
Tracked across 3 events · 49 articles · First seen May 25, 2026 · Last active Jul 21, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Menarini Group announced positive Phase 3 SENTRY trial data for selinexor plus ruxolitinib in myelofibrosis, which could lead to a new treatment option and enhance its market position in oncology.
Jun 14, 2026 · 8 articles
Tech
Impact: Menarini Group, along with its subsidiary AnBogen Therapeutics, Inc., presented new data related to elacestrant and tagraxofusp at the ASCO Annual Meeting, highlighting its commitment to oncology treatments and potentially boosting its product portfolio.
May 25, 2026 · 33 articles
Business
Impact: As parent company of Menarini Asia-Pacific, the Menarini Group benefits from the partnership through expanded market presence in Asia-Pacific.
Jul 21, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Menarini Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard